0 230

Cited 0 times in

Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"

DC Field Value Language
dc.contributor.author김나리-
dc.contributor.author성진실-
dc.date.accessioned2022-09-02T01:11:29Z-
dc.date.available2022-09-02T01:11:29Z-
dc.date.issued2020-08-
dc.identifier.issn0168-8278-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/190039-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfJOURNAL OF HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHCarcinoma, Hepatocellular* / surgery-
dc.subject.MESHHumans-
dc.subject.MESHLiver Neoplasms* / surgery-
dc.subject.MESHRadiofrequency Ablation*-
dc.subject.MESHRadiosurgery*-
dc.subject.MESHSorafenib-
dc.titleReply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?"-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Radiation Oncology (방사선종양학교실)-
dc.contributor.googleauthorNalee Kim-
dc.contributor.googleauthorJinsil Seong-
dc.identifier.doi10.1016/j.jhep.2020.04.016-
dc.contributor.localIdA05709-
dc.contributor.localIdA01956-
dc.relation.journalcodeJ01441-
dc.identifier.eissn1600-0641-
dc.identifier.pmid32467075-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0168827820302294-
dc.contributor.alternativeNameKim, Nalee-
dc.contributor.affiliatedAuthor김나리-
dc.contributor.affiliatedAuthor성진실-
dc.citation.volume73-
dc.citation.number2-
dc.citation.startPage468-
dc.citation.endPage469-
dc.identifier.bibliographicCitationJOURNAL OF HEPATOLOGY, Vol.73(2) : 468-469, 2020-08-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.